NEW YORK, NY – [Date of Article – can be current or slightly before Sept 17, 2026] – In a landmark decision poised to revolutionize personal mobility for individuals with spinal cord injuries, Wandercraft, a leading innovator in medical robotics, has announced that its groundbreaking personal self-balancing exoskeleton, Eve, has received clearance from the U.S. Food and Drug Administration (FDA). This pivotal regulatory approval marks a significant step forward, promising to extend hands-free upright mobility beyond the confines of rehabilitation centers and into the daily lives of eligible wheelchair users.
The FDA clearance for Eve represents more than just a technological achievement; it symbolizes a profound shift in how mobility challenges are addressed, offering new avenues for independence, participation, and an enhanced quality of life. For countless individuals whose opportunities to stand and move upright have historically been limited to clinical settings, Eve opens a world of possibilities, bringing the extraordinary potential of upright movement into the realm of ordinary, everyday moments.
Main Facts: A Paradigm Shift in Personal Mobility
Wandercraft’s Eve is engineered as a personal self-balancing exoskeleton, meticulously designed to support upright mobility in a hands-free manner. This innovative device is specifically intended for eligible adults living with spinal cord injuries at any level, empowering them to walk, bend, turn, and utilize their hands freely while standing. The device operates through a remote controller, managed by the user, and incorporates advanced self-balancing technology that differentiates it from many existing exoskeletons.
Crucially, Eve is not designed to replace wheelchairs but rather to complement them, expanding the spectrum of daily activities accessible to users. Imagine the simple yet profound acts of making coffee at a kitchen counter, reaching for a book on a high shelf, or engaging in eye-level conversations with friends and family on a patio – these are the moments Eve aims to make possible. Its intended use covers level indoor surfaces and immediately adjacent open-air areas that are part of a building, such as terraces, under the supervision of a specially trained companion.
The clearance is a direct result of Wandercraft’s extensive experience with its rehabilitation exoskeleton, Atalante X. Used in over 150 rehabilitation and research centers worldwide, Atalante X laid the foundational knowledge and technological prowess upon which Eve was built. The transition from a clinical-grade rehabilitation tool to a personal, home-use device signifies a maturation of exoskeleton technology, moving from assisted therapy to integrated daily living.
Chronology: From Rehabilitation to Personal Independence
The journey to Eve’s FDA clearance is a testament to years of dedicated research, development, and clinical validation. Wandercraft’s initial success with Atalante X established its credibility in the field of self-balancing exoskeletons. Atalante X, renowned for its dynamic balance capabilities and robotic intelligence, has been instrumental in neurorehabilitation, helping patients regain motor function and improve gait. This extensive experience provided an invaluable blueprint for developing a more compact, user-friendly, and personal version of the technology.
The conceptualization of Eve aimed to address a critical unmet need: bridging the gap between intensive rehabilitation and independent living. While Atalante X offered the benefits of upright mobility in a controlled clinical environment, the aspiration was to empower users to experience these benefits in their homes and communities. This vision led to the design and engineering of Eve, focusing on ease of use, safety, and adaptability to daily routines.
A multi-site clinical trial formed the bedrock of the FDA submission. This rigorous investigation, involving participants with a range of spinal cord injuries and their companions, was conducted at esteemed institutions including the James J. Peters Department of Veterans Affairs Medical Center in the Bronx, NY; Kessler Foundation in West Orange, NJ; and Walk in New York in New York City, NY. The trials meticulously assessed safety, function, the efficacy of training protocols, and the overall readiness of the device for personal use in everyday environments. The positive outcomes from these trials were instrumental in securing the FDA clearance.
Following this significant regulatory milestone, Wandercraft has set a definitive timeline for commercial availability. Eve is slated for an official commercial launch in the United States on September 17, 2026. This highly anticipated event will take place at the Cure healthcare innovation campus in New York City, presented in collaboration with the United Spinal Association, which will be celebrating its 80th anniversary. The event, designed to be livestreamed globally, will serve as a platform to unveil Eve to a broad audience, bringing together individuals with spinal cord injuries, caregivers, clinicians, researchers, policymakers, and the very pilots who have experienced Eve firsthand.
Wandercraft also anticipates that Eve could become eligible for Medicare reimbursement within 60 to 90 days post-clearance, under billing code K1007, a pathway established for eligible personal exoskeleton users since 2024 as part of the Durable Medical Equipment, Prosthetics, Orthotics, and Supplies (DMEPOS) program. This is a critical step towards making the technology financially accessible to a wider population, with plans to subsequently broaden patient access via private payers and other funding sources.
Before widespread commercial availability, a select group of qualified individuals will be offered an exclusive opportunity to experience Eve, providing early access to this transformative technology. Interested individuals are invited to request consideration through an online inquiry form, signifying Wandercraft’s commitment to a carefully managed and supported rollout.
Supporting Data: Clinical Validation and Societal Impact
The clinical evidence underpinning Eve’s FDA clearance is robust and comprehensive. The three-site clinical trial focused not only on the engineering performance of the device but, crucially, on how users and their trained companions could safely and effectively integrate Eve into real-world activities. Participants represented a diverse range of injury severities, undertaking structured training before engaging in functional, usability, and task-based assessments designed to mirror the demands of daily life.
The trial successfully demonstrated that both participants and their companions could proficiently learn to operate Eve and execute activities relevant to personal use. Participants achieved key functional and usability endpoints, including measurable improvements in walking performance and the ability to perform activities of daily living while upright. This data provides concrete validation of Eve’s practical utility and its potential to enhance independence.
Dr. Gail Forrest, PhD, director of the Tim and Caroline Reynolds Center for Spinal Stimulation at Kessler Foundation, highlighted the significance of these findings: "What makes these findings meaningful is that the technology was evaluated not only on engineering performance but also on how users and companions could safely integrate it into real-world activities. The combination of functional performance, usability, and user-reported outcomes gives this technology substantial clinical relevance." The studies conducted at the James J. Peters VA Medical Center further reinforced how Wandercraft’s technology has advanced to meet the practical needs of people with spinal cord injuries, bringing state-of-the-art robotics closer to personal application.
Beyond objective performance metrics, the subjective experiences of participants in the clinical trials offered compelling insights into the profound impact of upright mobility. Users reported improvements across several critical aspects of daily life, extending far beyond mere physical movement. These included enhanced physical health status, significant psychological well-being, increased endurance during daily activities, and a reduction in lower-limb spasticity. Furthermore, some participants experienced improvements in sitting balance, sleep quality, and even bladder and bowel function – benefits that underscore the holistic advantages of standing and walking. These findings resonate deeply with the statistics provided by the Christopher & Dana Reeve Foundation, which reports that over five million people in the United States live with paralysis, including hundreds of thousands with spinal cord injuries. For this vast population, the ability to stand and move upright represents not just physical capability but a deeply meaningful experience that positively affects social interactions, mental health, and overall participation in society.
Official Responses: Vision, Empowerment, and Access
Matthieu Masselin, co-founder and CEO of Wandercraft, articulated the profound significance of this milestone: “FDA clearance of Eve marks one of the most important moments in Wandercraft’s history and a significant step for the people, families, clinicians, researchers, and partners who helped make it possible. Together, Atalante X and Eve may offer eligible users a pathway from walking during rehabilitation to upright mobility at home, whether making coffee at the kitchen counter, reaching for a book, or spending time with friends on the patio.” Masselin’s statement underscores Wandercraft’s comprehensive vision: a continuum of care that seamlessly transitions from intensive clinical therapy to sustained personal independence.
The lived experience of this transformation was eloquently captured by Caroline Laubach, a Wandercraft Test Pilot: “For years, I experienced much of the world while seated. Using Eve transformed ordinary moments in ways I never expected, like having conversations eye-to-eye whether seated or standing, getting a cup from the highest kitchen cabinet, and simply bringing a new type of confidence into my life.” Laubach’s testimony highlights the often-overlooked psychological and social benefits of upright mobility – the restoration of dignity, the ease of social interaction, and the profound sense of empowerment that comes with reclaiming physical capabilities.
Wandercraft has also made a strong commitment to ensuring widespread access to Eve. Recognizing that technological innovation is only truly valuable when it is accessible, the company has invested substantially in establishing a robust support system. This includes a dedicated group of access specialists who will guide users and their care teams through the complexities of claim submissions, coverage requirements, reimbursement questions, and available financing options. This proactive approach to navigating the healthcare landscape demonstrates Wandercraft’s holistic commitment to its users, ensuring that the path to acquiring and utilizing Eve is as smooth as possible.
The company has forged strategic partnerships to build the necessary infrastructure for Eve’s distribution, training, and service. These partnerships include:
- Walk US: A key partner for Eve evaluations, training, demonstrations, and community education, specializing in neurorehabilitation using Atalante X. A second location, Walk in Miami by Wandercraft, is anticipated to open later this year.
- National Seating & Mobility: North America’s largest provider of complex rehabilitation technology, serving as Wandercraft’s exclusive CRT distribution partner for Eve. Their extensive network of over 180 locations across the U.S. and Canada will facilitate evaluation, access, delivery, and service.
- Good Shepherd Rehabilitation: The exclusive Eve partner in Pennsylvania’s Lehigh Valley, offering information and access to the technology at their Hyland Center.
- USVetServ: A Service-Disabled Veteran-Owned Small Business, authorized as an independent distributor of Eve and Atalante X for the U.S. Department of Veterans Affairs (VA) and its facilities nationwide, underscoring Wandercraft’s commitment to veterans.
These collaborations collectively form a comprehensive ecosystem designed to translate FDA clearance into tangible, meaningful access for eligible users across diverse geographical and demographic segments.
Implications: Reshaping the Future of Assistive Technology
The FDA clearance of Wandercraft’s Eve represents a monumental stride forward, with far-reaching implications for individuals with spinal cord injuries, the broader field of assistive technology, and the future of healthcare robotics.
For Individuals with Spinal Cord Injuries: The most immediate and profound implication is the promise of enhanced independence and quality of life. The ability to perform daily activities hands-free and upright can mitigate numerous secondary health complications associated with prolonged sitting, such as pressure sores, muscle atrophy, and cardiovascular issues. Beyond physical benefits, the psychological uplift from regaining upright posture, eye-level interaction, and the ability to navigate personal spaces independently cannot be overstated. It fosters a renewed sense of self-worth, social inclusion, and active participation in family and community life.
Advancements in Assistive Technology: Eve sets a new benchmark for personal exoskeletons. Its self-balancing technology, moving beyond the traditional reliance on crutches or external supports, signifies a maturation in robotic gait assistance. This development is likely to spur further innovation in the field, encouraging other manufacturers to explore more sophisticated, autonomous, and user-centric designs. The integration of advanced robotics, sensors, and artificial intelligence in devices like Eve paves the way for future assistive technologies that are more intuitive, adaptable, and seamlessly integrated into users’ lives. The success of Eve could accelerate research into exoskeletons for other conditions causing mobility impairments, such as stroke, multiple sclerosis, or cerebral palsy.
Healthcare and Rehabilitation Paradigm Shift: By bridging the gap between clinical rehabilitation and home use, Eve challenges existing healthcare paradigms. It underscores the potential for medical devices to move beyond acute care and become long-term, personal solutions for chronic conditions. This shift will necessitate evolving training protocols, reimbursement models, and healthcare provider roles. The structured training program – five two-hour sessions covering transfers, remote control operation, walking, navigating tight spaces, activities of daily living, and emergency procedures – highlights the importance of comprehensive education for safe and effective home use. This also implies a greater emphasis on companion training and support, recognizing the collaborative effort often required for advanced assistive technologies.
Economic and Social Impact: The widespread adoption of devices like Eve could have significant economic implications. By reducing secondary complications and enhancing independence, it could potentially lower long-term healthcare costs associated with paralysis. Socially, it promotes greater inclusion and participation of individuals with disabilities, fostering more diverse and equitable communities. The partnership with USVetServ, specifically targeting veterans, also highlights the commitment to supporting those who have served, offering them access to cutting-edge rehabilitation and mobility solutions.
Challenges and Opportunities: While the future is bright, challenges remain. The cost of advanced exoskeletons can be substantial, making robust reimbursement pathways and financing options critical for broad access. Continued research into long-term safety, durability, and the evolving needs of users will also be essential. However, the opportunities are immense – from refining the technology for even greater versatility (e.g., navigating uneven outdoor terrain) to exploring integration with smart home systems and other personal health technologies.
In conclusion, Wandercraft’s Eve is more than just a device; it is a beacon of hope for millions, a testament to human ingenuity, and a powerful symbol of progress in the ongoing quest to empower individuals with disabilities. Its FDA clearance marks a new chapter in personal mobility, promising to transform lives by enabling the simple yet profound act of standing tall and moving forward, one step at a time, in the comfort and familiarity of one’s own world.
Learn more at: Wandercraft.eu.
Featured image: Woman using Wandercraft Eve self-balancing personal exoskeleton to stand. Photo: Wandercraft
